clonoSEQ growth now carries almost everything
- MRD revenue was $67.1 million in Q1 2026, up 53% from a year earlier.
- clonoSEQ test volume grew 41% in Q1 2026, showing strong demand from doctors and drug companies.
- MRD made up 95% of Q1 2026 revenue, so Adaptive is now highly tied to one product line.
- Management raised 2026 MRD revenue guidance to $260 million to $270 million.
- Immune Medicine revenue fell 57% in Q1 2026 after the Genentech deal ended.
- The stock still needs clean execution, because the market already expects a lot from clonoSEQ.
A sharper MRD story
Adaptive is becoming a much simpler company. The main story is clonoSEQ, its test for minimal residual disease, which means tiny amounts of cancer left after treatment. In Q1 2026, MRD revenue grew 53%, and clonoSEQ volume grew 41%.
The bull case is that clonoSEQ keeps spreading through hospital systems, community cancer clinics, and drug company trials. Management now expects 2026 MRD revenue of $260 million to $270 million and clinical volume growth of at least 35%. A 17% Medicare price increase that took effect in 2025 also helps revenue per test.
The bear case is just as clear. MRD was 95% of Q1 2026 revenue. If clonoSEQ growth slows, if payers push back, or if a rival takes share, Adaptive has little else big enough to soften the hit.
The Immune Medicine business still has scientific value, but it is no longer the second leg it used to be. The Genentech collaboration ended, and Pfizer agreements signed in December 2025 may help, but their financial size is still an open question.
Paid per test, plus platform deals
Adaptive makes money in two reported segments: MRD and Immune Medicine. MRD is the core business. It sells clonoSEQ testing to doctors who monitor blood cancers and to biopharma companies that use the test in drug studies.
Immune Medicine sells immunosequencing research services, data licensing, and discovery partnerships. Immunosequencing means reading immune-cell receptors to learn what the immune system has seen. This can help research in cancer, autoimmune disease, and drug discovery.
The model works best when clonoSEQ volume rises faster than costs. That is why the path to positive Adjusted EBITDA by the end of 2026 matters. Adjusted EBITDA is a profit measure that strips out items like interest, taxes, depreciation, amortization, and some other costs.
The weak point is concentration. Adaptive has cut back internal drug work, including an ankylosing spondylitis antibody program, and it lost the Genentech collaboration. That makes the diagnostics business more important than ever.
What Adaptive sells
clonoSEQ for clinical care
clonoSEQ is Adaptive's main product. It helps doctors detect and monitor tiny traces of cancer in multiple myeloma, B cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and other lymphoid cancers.
clonoSEQ for biopharma trials
Drug companies use clonoSEQ testing in studies to measure how well cancer drugs clear disease. This creates revenue tied to sample testing and regulatory milestones.
Adaptive Immunosequencing
This service reads immune receptor data for biopharma and academic researchers. It is useful science, but it is much smaller than MRD today.
TCR discovery and antigen maps
Adaptive uses immune receptor data to connect T cells with the targets they recognize. The company has worked on this area with Microsoft and signed Pfizer agreements for rheumatoid arthritis and broader immunology research.
Therapeutic collaborations
This used to include a major Genentech cellular therapy collaboration. That deal was terminated in August 2025 and became effective in February 2026, so future value depends on new partners.
One segment now dominates
The mix is from the three months ended March 31, 2026. MRD was 95% of revenue, which makes clonoSEQ growth the key number to watch.
What could go wrong
clonoSEQ concentration
High impact · High oddsMRD made up 95% of Q1 2026 revenue. That means one product line now drives almost the whole company. A slowdown in clonoSEQ would show up quickly in Adaptive's results.
Adoption slows before profits arrive
High impact · Medium oddsManagement expects clinical volume growth of at least 35% in 2026. Q1 volume growth was 41%, but that pace may get harder as the market matures. If growth falls too soon, the path to positive Adjusted EBITDA could stretch out.
Payer and lab test rules change
High impact · Medium oddsclonoSEQ benefited from a 17% Medicare price increase in 2025. Management also said clonoSEQ is not subject to PAMA reporting for the current cycle. Still, lab test pricing and the FDA's new framework for laboratory developed tests could raise costs or pressure payment over time.
Immune Medicine lacks a new floor
Medium impact · High oddsImmune Medicine revenue was $3.8 million in Q1 2026, down 57% from a year earlier. The main reason was the end of the Genentech collaboration. Pfizer agreements may help, but the company has not given enough detail to prove a stable revenue base.
The price leaves little room for errors
Medium impact · Medium oddsThe company is executing better, but investors are already giving clonoSEQ a lot of credit. If revenue growth, margins, or guidance disappoint, the stock could react badly. This is especially true because diversification has weakened.
In one breath
What does Adaptive Biotechnologies do?
Adaptive reads immune-system data and sells tests and research services based on that data. Its main product is clonoSEQ, a cancer monitoring test for minimal residual disease.
Why is clonoSEQ important?
clonoSEQ helps detect very small amounts of cancer left after treatment. In Q1 2026, the MRD segment built around clonoSEQ was 95% of Adaptive's revenue.
Is Adaptive profitable?
Adaptive is trying to reach consolidated positive Adjusted EBITDA by the end of 2026. The MRD segment is growing fast enough to make that goal look more realistic, but execution still matters.
What happened to the Genentech deal?
Genentech terminated its collaboration with Adaptive in August 2025, with the termination effective in February 2026. That hurt the Immune Medicine segment and made Adaptive more dependent on clonoSEQ.